[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-460629-105":59,"doc-detail-460629-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","long-term-use-of-tralokinumab-in-patients-with-atopic-dermatitis-a-real-world-multicentric-case-series-short-communication","Long-Term Use of Tralokinumab in Patients With Atopic Dermatitis - A Real-World Multicentric Case Series - short communication","","Long-term tralokinumab effectiveness and safety were assessed in 13 adult patients with atopic dermatitis treated at five Austrian dermatology clinics. The median treatment duration was 29 (13–35) months, with 92% receiving therapy for over 1 year. EASI, IGA, and PP-NRS scores showed marked improvement over median follow-up periods, with most patients achieving IGA 0–1 at last assessment. Treatment-emergent adverse events were generally manageable, and dry eye-related symptoms typically resolved over time.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/long-term-use-of-tralokinumab-in-patients-with-atopic-dermatitis-a-real-world-multicentric-case-series-short-communication/460629/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/long-term-use-of-tralokinumab-in-patients-with-atopic-dermatitis-a-real-world-multicentric-case-series-short-communication/460629.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",16,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the objective of this multicentric case series?","Question",{"text":113,"@type":114},"To evaluate the real-world effectiveness, safety, and tolerability of long-term tralokinumab in adult patients with atopic dermatitis treated at five clinics in Austria.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was effectiveness assessed and what changes were observed?",{"text":118,"@type":114},"Effectiveness was measured using EASI, IGA, and PP-NRS. Scores dropped substantially from baseline to the most recent assessments, with many patients reaching IGA 0–1.",{"name":120,"@type":111,"acceptedAnswer":121},"What safety or tolerability issues were reported during long-term treatment?",{"text":122,"@type":114},"Dry eye-related events (dry eyes, blepharitis, and/or conjunctivitis) occurred in some patients and generally resolved over time. Other adverse events included herpes simplex infection, head/neck dermatitis, worsening dust mite allergy, hair loss, and respiratory infections.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},460629,1790812155,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":39,"preview_page_count":4},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","International Journal of Dermatology  \nSHORT COMMUNICATION  OPEN ACCESS   \nLong-Term Use of Tralokinumab in Patients With Atopic Dermatitis: A Real-World Multicentric Case Series  \nChristine Bangert1  | Barbara Ebner2 | Barbara Gruber3 | Damian Meyersburg4 | Judith Traxler5  \n1Department of Dermatology, Medical University of Vienna, Vienna, Austria | 2Department of Dermatology and Venereology, Elisabethinen Hospital, Linz, Austria | 3Department of Dermatology and Venereology, Klinikum Wels-Grieskirchen, Wels, Austria | 4Department of Dermatology and Allergology, University Hospital Salzburg of the Paracelsus Medical University, Salzburg, Austria | 5Department of Dermatology and Venereology, Kepler University Hospital, Linz, Austria  \nCorrespondence: Christine Bangert ([christine.bangert@meduniwien.ac.at](christine.bangert@meduniwien.ac.at))  \nReceived: 24 April 2025 | Accepted: 2 June 2025  \nFunding: Medical writing support was provided by Steph Carter (Lyrical Medical Writing Services Ltd) and funded by LEO Pharmaceutical Products Sarath Ltd, Austria.  \nKeywords: atopic dermatitis | case series | long-term effectiveness | long-term safety | real-world evidence | tralokinumab  \nTralokinumab is a human immunoglobulin G4 monoclonal antibody approved for treating moderate-to-severe atopic dermatitis (AD) . Since its regulatory approval, several studies have evaluated the performance of tralokinumab in real-world settings, though results have been limited to the first year of treatment [1–4] . This case series aimed to assess the real-world effectiveness, safety, and tolerability of long-term tralokinumabuse in adult patients with AD treated at five dermatology clinics in Austria between August 16, 2021, and July 30, 2024. All patients provided informed consent for inclusion in this study and for their anonymized data to be published in related publications. Effectiveness was evaluated using the Eczema Area and Severity Index (EASI), the Investigator Global Assessment (IGA), and the Peak Pruritus Numerical Rating Scale (PP-NRS) .  \nThis case series included 13 patients (six male and seven female) with a median age of 33 years (Table 1) . Previous AD treatments consisted of topical corticosteroids (85% of patients), phototherapy (54%), dupilumab (54%), systemic corticosteroids (31%), and calcineurin inhibitors (31%) . The median (interquartile range [IQR]) treatment duration for tralokinumab was 29 (13–35) months. Most patients (92%) had received tralokinumab for over 1 year, and four had been on treatment for approximately 3 years. Only one patient discontinued tralokinumab, which was  \ndue to pregnancy rather than side effects or dissatisfaction with treatment effectiveness.  \nFive patients experienced dry eyes, blepharitis, and/or conjunctivitis with tralokinumab, but these generally resolved overtime. Other treatment-emergent adverse events included herpes simplex infection (n = 2), head/neck dermatitis (n = 1), worsening of dust mite allergy (n = 1), hair loss (n = 1), and respiratory infection (n = 1) . The hair loss was mild, resolved within three months, and the relationship to tralokinumab was uncertain. Five patients had previously experienced conjunctivitis while on dupilumab. Of these, four reported that the condition had resolved, and one noted an improvement following the transition to tralokinumab.  \nThe median (IQR) EASI score dropped from 11.2 (4.4–15.3) at the start of tralokinumab treatment to 1.3 (0 .1–3. 1) at the most recent EASI assessment (with a median follow-up of 23.5 months) . Similar reductions were noted for other parameters, with median (IQR) IGA declining from 3.0 (3.0–4.0) to 1.0 (0.0–1.0) and PP-NRS falling from 4.5 (3.8–8.0) to 1.0 (0.5–2.5) over median follow-up periods of 18.0 and 23.0 months, respectively (Figure 1) . Most patients (9 out of 12; 75%) achieved an IGA score of 0 or 1 at their most recent assessment. Of the nine  \nThis is an open access article under the terms of the Creative Comm","cbCaidCOyyLBGna7","https://ap.wps.com/l/cbCaidCOyyLBGna7","pdf",184236,"English","# Background and objective\n# Patient characteristics and treatment exposure\n# Effectiveness outcomes\n# Safety and tolerability","[{\"question\":\"What was the objective of this multicentric case series?\",\"answer\":\"To evaluate the real-world effectiveness, safety, and tolerability of long-term tralokinumab in adult patients with atopic dermatitis treated at five clinics in Austria.\"},{\"question\":\"How was effectiveness assessed and what changes were observed?\",\"answer\":\"Effectiveness was measured using EASI, IGA, and PP-NRS. Scores dropped substantially from baseline to the most recent assessments, with many patients reaching IGA 0–1.\"},{\"question\":\"What safety or tolerability issues were reported during long-term treatment?\",\"answer\":\"Dry eye-related events (dry eyes, blepharitis, and/or conjunctivitis) occurred in some patients and generally resolved over time. Other adverse events included herpes simplex infection, head/neck dermatitis, worsening dust mite allergy, hair loss, and respiratory infections.\"}]","Long-Term Use of Tralokinumab in Patients With Atopic Dermatitis - A Real-World Multicentric Case Series - short communication | PDF",1790758937]